TMIST breast cancer screening trial begins to enroll nearly 165,000 women

(ECOG-ACRIN Cancer Research Group) Nearly 50 million screening mammograms occur each year yet there is no scientific evidence that the newer 3-D method tops conventional 2-D at detecting aggressive breast cancers early. The TMIST trial aims to find out. Data and biospecimens from participants may also facilitate ‘precision prevention.’ With the genetic revolution, this kind of trial has to happen to link genetics to screening for the benefit of women who may be at risk for breast cancer.